If 2020 started on a gloomy note on account of the threat of Covid-19, the year is closing on a hopeful one. On December 2, the world’s first vaccine against Covid-19, developed by American pharma giant Pfizer and German company BioNTech, received emergency authorisation in the UK, setting the stage for its immediate rollout.
The vaccine uses the mRNA technology platform and is reported to have 95 per cent efficacy in phase-III trials, but it faces significant distribution challenges. It must be stored at minus 70 degrees Celsius, a temperature for which India’s cold chain network is not ready. Pfizer said the vaccine would be transported in thermal shippers using dry ice to maintain the required temperature. These can be used as temporary storage units for 15 days by topping up the dry ice. The company has set the initial price of the vaccine at $39 for the two-dose regimen.
As initial doses of the vaccine are pre-booked by countries such as the US and the UK, India is unlikely to get it soon. “Our doors are open for these vaccines, should the need and the possibilities arise,” said Dr Vinod K. Paul, chairman of the National Expert Group on Vaccine Administration for Covid-19, in a recent conversation with public health experts.
This story is from the December 13, 2020 edition of THE WEEK.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 8,500+ magazines and newspapers.
Already a subscriber ? Sign In
This story is from the December 13, 2020 edition of THE WEEK.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 8,500+ magazines and newspapers.
Already a subscriber? Sign In
Between hospital and home
Transitional care centres can add a lot to India's health care system
EFFORT VS EFFECT
The government's attempts to ensure quality drugs is evident, but how well new policies can be monitored on the ground remains to be seen
A way to let go of fear
Accepting the use of adult diapers is a journey with various stages-denial, concealment, rejection and reluctance
Mandeeps & a miracle
Two strangers, one deadly disease and an act of kindness. How Mandeep Mann saved Mandeep Singh, an acute leukaemia patient, by donating his stem cells
The A, B, C of cosmetic surgery
Between eight to 10 lakh cosmetic surgeries happen in India every year. Who is an ideal candidate, and what are the risks and results you can expect?
Vaccines and meningitis
In sub-Saharan Africa, from Senegal in the west to Ethiopia in the east, and encompassing the northern part of Nigeria, there exists a region known as the African Meningitis Belt (AMB).
Celebrating diversity and inclusivity
As Indians battle it out in our nation's 18th general election, it is again time for voters to reflect on the \"Idea of India\"-or rather, on two duelling ideas of India that are now before us and between which the nation must choose at the ballot box.
Defendant: an Hermès handbag
When Hermès was hit with a class-action lawsuit last month for \"antitrust\" activities, it didn't see it coming. Most of the luxury world has all eyes on this suit, filed by two interested consumers who claim they were denied a purchase, and whether it would go to trial.
A legacy, bound
Amal Allana's biography of her father, Ebrahim Alkazi, is as much personal as it is historical
Cutting-edge chronicle
In his new book, Salman Rushdie's pen is mightier than the knife